Want to see HK:6127 full AI Analyst Report?
6127 Stock Chart & Stats
HK$21.12
HK$0.01(0.12%)
At close: 4:00 PM EST
HK$21.12
HK$0.01(0.12%)
Day’s Range― - ―
52-Week RangeHK$15.13 - HK$28.70
Previous CloseN/A
Volume546.17K
Average Volume (3M)6.46M
Market Cap
HK$31.09B
Enterprise ValueHK$23.32B
Total Cash (Recent Filing)HK$2.49B
Total Debt (Recent Filing)HK$12.48M
Price to Earnings (P/E)59.7
Beta1.46
Next Earnings
Sep 01, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend Yield0.15%
Share Statistics
EPS (TTM)0.66
Shares Outstanding118,995,210
10 Day Avg. Volume2,397,586
30 Day Avg. Volume6,458,364
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.65
Price to Sales (P/S)8.31
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.63
Revenue Forecast (FY)HK$2.21B
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthExtremely low leverage and an equity-heavy capital base provide durable financial flexibility. This reduces funding costs and refinancing risk, supports investment in capacity or technology, and gives the firm resilience through R&D spending cycles and industry downturns over months.
Cash GenerationPositive operating cash flow underpins the business's ability to fund operations, service clients, and cover routine capital needs without relying on debt. Over the medium term this supports steady service delivery, dividend capacity, and selective reinvestment into labs or capability upgrades.
Business Model - CRO ServicesA fee-for-service CRO model tied to preclinical R&D provides recurring, contract-backed revenue from diversified drug and device developers. Structural outsourcing trends in pharma R&D make demand for specialized preclinical services relatively durable, supporting medium-term revenue visibility.
Bears Say
Revenue Decline & Margin CompressionA sustained top-line decline plus sharp gross-margin compression indicate weakening pricing power or rising direct costs. These trends reduce reinvestment capacity and make future margin recovery harder, threatening long-term profitability unless structural revenue drivers improve.
Free Cash Flow VolatilityMaterial swings in free cash flow undermine the predictability of funds available for capex, dividends, or strategic investments. Persistent volatility raises risk that the firm must cut distributions or delay upgrades in weaker periods, impairing steady long-term operational improvement.
Modest Returns On EquityWith an equity-heavy capital structure, modest ROE suggests the company is not efficiently converting its capital base into profits. Unless operating margins or asset turnover improve, shareholder returns may lag and capital allocation effectiveness could remain a structural constraint.
JOINN Laboratories (China) Co., Ltd. Class H News
6127 FAQ
What was JOINN Laboratories (China) Co., Ltd. Class H’s price range in the past 12 months?
JOINN Laboratories (China) Co., Ltd. Class H lowest stock price was HK$15.13 and its highest was HK$28.70 in the past 12 months.
What is JOINN Laboratories (China) Co., Ltd. Class H’s market cap?
JOINN Laboratories (China) Co., Ltd. Class H’s market cap is HK$31.09B.
When is JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date?
JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date is Sep 01, 2026 which is in 60 days.
How were JOINN Laboratories (China) Co., Ltd. Class H’s earnings last quarter?
JOINN Laboratories (China) Co., Ltd. Class H released its earnings results on Apr 29, 2026. The company reported HK$0.367 earnings per share for the quarter, beating the consensus estimate of HK$0.069 by HK$0.298.
Is JOINN Laboratories (China) Co., Ltd. Class H overvalued?
According to Wall Street analysts JOINN Laboratories (China) Co., Ltd. Class H’s price is currently Overvalued.
Does JOINN Laboratories (China) Co., Ltd. Class H pay dividends?
JOINN Laboratories (China) Co., Ltd. Class H pays a Annually dividend of HK$0.138 which represents an annual dividend yield of 0.15%. See more information on JOINN Laboratories (China) Co., Ltd. Class H dividends here
What is JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate?
JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate is 0.09.
How many shares outstanding does JOINN Laboratories (China) Co., Ltd. Class H have?
JOINN Laboratories (China) Co., Ltd. Class H has 118,995,210 shares outstanding.
What happened to JOINN Laboratories (China) Co., Ltd. Class H’s price movement after its last earnings report?
JOINN Laboratories (China) Co., Ltd. Class H reported an EPS of HK$0.367 in its last earnings report, beating expectations of HK$0.069. Following the earnings report the stock price went down -1.439%.
Which hedge fund is a major shareholder of JOINN Laboratories (China) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6127
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JOINN Laboratories (China) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.02%
12-Months-Change
Fundamentals
Return on Equity
5.98%
Trailing 12-Months
Asset Growth
12.65%
Trailing 12-Months
Company Description
JOINN Laboratories (China) Co., Ltd. Class H
Joinn Laboratories (China) Co., Ltd. is a global provider of essential preclinical and non-clinical research services, operating across the United States, mainland China, and various international markets. The company organizes its operations into three primary divisions: Non-Clinical Studies, Clinical Trial and Related Services, and Research Model Sales. The Non-Clinical Studies segment specializes in comprehensive drug safety assessments, pharmacokinetic and drug metabolism research, and pharmacology and efficacy investigations. Within its Clinical Trial and Related Services segment, the firm delivers clinical contract research organization (CRO) support, co-manages specialized Phase I clinical research facilities, and provides bioanalytical testing. The Research Model Sales division is responsible for the development, breeding, and distribution of diverse animal models for research purposes, encompassing non-human primates and rodents. Furthermore, Joinn Laboratories also extends its offerings to include investment management and cell-based assay (CBA) services. Established in 1995, the company is headquartered in Beijing, China.
Technical Analysis
Genscript Biotech
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---